Free tool
FAERS Monitor: Qalsody
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215887 or its brand name (Qalsody, Tofersen). Reports on generic versions are filed under their own applications.
Reports
567
Serious
309
54% of reports
Hospitalization
143
Death reported
125
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- amyotrophic lateral sclerosis66
- death57
- headache57
- procedural pain46
- post lumbar puncture syndrome35
- fall27
- csf protein increased26
- back pain23
- fatigue23
- muscular weakness20
- pain in extremity20
- pain19
- pneumonia19
- asthenia18
- dyspnoea18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 57 |
| 2024 | 166 |
| 2025 | 189 |
| 2026 | 155 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,592 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| post lumbar puncture syndromeSignal | 35 | 1293.1 | 932.6 | 42,431 |
| csf protein increasedSignal | 26 | 1202.3 | 820.7 | 29,077 |
| amyotrophic lateral sclerosisSignal | 66 | 1172.6 | 930.9 | 73,769 |
| procedural painSignal | 46 | 61.6 | 46.7 | 2,682 |
| muscular weaknessSignal | 20 | 6.5 | 4.2 | 89 |
| back painSignal | 23 | 3.7 | 2.5 | 43 |
| headacheSignal | 57 | 3.4 | 2.6 | 96 |
| fallSignal | 27 | 3.0 | 2.1 | 35 |
| pain in extremitySignal | 20 | 2.5 | 1.6 | 17 |
| deathSignal | 57 | 2.5 | 1.9 | 50 |
| pneumoniaSignal | 19 | 2.2 | 1.4 | 11 |
| asthenia | 18 | 1.8 | 1.1 | 5 |
| dyspnoea | 18 | 1.2 | 0.7 | 0 |
| pain | 19 | 1.1 | 0.7 | 0 |
| fatigue | 23 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.